Traditional Chinese medicine composition for treating ischemic cardiomyopathy and application thereof
Through traditional Chinese medicine compositions, including Prince Ginseng, Red Ginseng, Astragalus, Ophiopogon japonicus, Schisandra chinensis, fried white peony, Salvia miltiorrhiza and licorice, the limitations of ischemic cardiomyopathy treatment have been solved, and the symptoms and heart function have been significantly improved, and the quality of life has been improved. , combined with Western medicine, the effect is better.
Patent Information
- Application Number
- CN202411060360.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-08
AI Technical Summary
The treatment methods for ischemic cardiomyopathy have limitations and lack significant therapeutic effects, especially in the field of traditional Chinese medicine, which leads to poor prognosis and high mortality rate.
Provided is a traditional Chinese medicine composition, including genus ginseng, red ginseng, astragalus, Ophiopogon japonicus, Schisandra chinensis, fried white peony, salvia miltiorrhiza and licorice, for the preparation of a pharmaceutical composition for the treatment of ischemic cardiomyopathy, used in the form of an oral preparation, alone Or combined with Western medicine.
Significantly improve the symptoms of ischemic cardiomyopathy, especially those with Qi and Yin deficiency, improve quality of life, improve cardiac function, improve cardiac ejaculation fraction, reduce myocardial fibrosis and mitochondrial autophagy, and reduce inflammation indicators.
Smart Images

Figure BDA0004977674910000091 
Figure BDA0004977674910000101 
Figure BDA0004977674910000102
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicine and pharmacy, and specifically relates to a traditional Chinese medicine composition for ischemic cardiomyopathy and application thereof. Background Art
[0002] Ischemic cardiomyopathy (ICM) was first proposed by Burch in 1970. ICM is currently defined as a clinical syndrome of a series of manifestations such as myocardial fibrosis caused by long-term myocardial ischemia, leading to cardiac systolic and / or diastolic dysfunction, cardiac enlargement or stiffness, heart failure, and arrhythmia. It is a special type of stable coronary heart disease. According to the current diagnostic criteria for ICM and the staging of heart failure, ICM has organic heart disease and laboratory evidence of heart failure, and belongs to the BD stage of heart failure. The number of ICM patients worldwide has reached 125 million, and its incidence rate is still rising. ICM has a poor prognosis and a high mortality rate, which seriously endangers human life safety. However, Western medicine has certain limitations in its treatment. Although the "Guidelines for the Diagnosis and Treatment of Heart Failure in China 2024" has included traditional Chinese medicine as one of the methods for treating heart failure, there is still a lack of effective treatment methods, which is not conducive to the standardized treatment of ICM with traditional Chinese medicine.
[0003] In view of this, there is an urgent need for a drug with good efficacy and few side effects for treating ischemic cardiomyopathy. Summary of the invention
[0004] In order to overcome the defects of the prior art, the object of the present invention is to provide a Chinese medicine composition that can significantly improve the symptoms of ischemic cardiomyopathy.
[0005] Solutions for solving problems
[0006] On the one hand, the present invention provides a traditional Chinese medicine composition for treating ischemic cardiomyopathy, comprising the following raw materials in parts by weight: 1-20 parts of Pseudostellariae Radix or red ginseng, 10-50 parts of Astragalus, 5-30 parts of Ophiopogon japonicus, 1-15 parts of Schisandrae Chinensis, 1-20 parts of stir-fried white peony root, 5-30 parts of Salvia miltiorrhiza, and 0.1-10 parts of Licorice.
[0007] Preferably, the Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of Pseudostellariae Radix or Red Ginseng, 15-40 parts of Astragalus, 5-25 parts of Ophiopogon japonicus, 1-10 parts of Schisandrae Chinensis, 5-15 parts of stir-fried White Peony Root, 5-25 parts of Salvia miltiorrhiza, and 1-5 parts of Licorice.
[0008] Preferably, the Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of Radix Pseudostellariae or Red Ginseng, 30 parts of Radix Astragali, 15 parts of Radix Ophiopogonis, 6 parts of Schisandrae Chinensis, 10 parts of stir-fried white peony root, 15 parts of Radix Salviae Miltiorrhizae, and 3 parts of Radix Glycyrrhizae.
[0009] Preferably, the Chinese medicine composition is composed of Radix Pseudostellariae, Radix Astragali, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Radix Paeoniae Alba, Radix Salviae Miltiorrhizae and Radix Glycyrrhizae, and the weight proportion of each raw material is as defined in any one of the above items.
[0010] Preferably, the Chinese medicine composition is composed of red ginseng, astragalus, ophiopogon, schisandra, stir-fried white peony root, salvia miltiorrhiza and liquorice, and the weight proportion of each raw material is as defined in any one of the above items.
[0011] In one aspect, the present invention provides a pharmaceutical composition, comprising any one of the above-mentioned traditional Chinese medicine compositions.
[0012] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0013] In one aspect, the present invention provides a method for preparing a pharmaceutical composition, wherein the bulk drug according to any of the above-mentioned weight portions is added or not added with a pharmaceutically acceptable carrier to prepare a clinically acceptable preparation.
[0014] In one aspect, the present invention provides use of any of the above-mentioned traditional Chinese medicine compositions, the above-mentioned drug combinations, or the drug compositions prepared according to the above-mentioned preparation methods in the preparation of drugs for treating ischemic cardiomyopathy.
[0015] Preferably, the drug is in the form of an oral preparation.
[0016] Preferably, the oral preparation is selected from one or more of decoctions, powders, capsules, tablets, honey pills, water-honey pills, water pills, concentrated pills, paste pills, wax pills, granules, oral liquids or dropping pills, more preferably decoctions, powders, capsules or tablets.
[0017] Effects of the Invention
[0018] The Chinese medicine composition provided by the present invention can significantly improve the symptoms of ischemic cardiomyopathy, especially when used in combination with Western medicine, it can more effectively improve the TCM symptoms of patients with Qi and Yin deficiency type ICM, improve the quality of life of patients, improve the exercise tolerance of patients, improve the cardiac function of patients, and increase the cardiac ejection fraction. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Representative myocardial tissue H&E staining images of rats in each group (200×).
[0020] Figure 2 Representative Masson staining images of myocardial tissues of rats in each group (200×), among which #### compared with the Sham group, P<0.0001; **** compared with the Model group, P<0.0001.
[0021] Figure 3 Comparison of mitochondrial morphology in myocardial tissue of rats in each group (6000×, 1μm).
[0022] Figure 4 This is the effect of Shenqi Yangxin Decoction on NT-proBNP and sST2 in H9c2 cardiomyocytes. Among them, #### compared with the Control group, P<0.0001; * compared with the Model group, P<0.05; **** compared with the Model group, P<0.0001.
[0023] Figure 5 The effect of Shenqi Yangxin Decoction on autophagy-related mRNA in H9c2 cardiomyocytes. Among them, #compared with the Control group, P<0.05; ###compared with the Control group, P<0.001; ####compared with the Control group, P<0.0001; **compared with the Model group, P<0.01; ***compared with the Model group, P<0.001; ****compared with the Model group, P<0.0001.
[0024] Figure 6 This is the effect of Shenqi Yangxin Decoction on autophagy-related proteins in H9c2 cardiomyocytes. Among them, #compared with the Control group, P<0.05; ###compared with the Control group, P<0.001; ####compared with the Control group, P<0.0001; **compared with the Model group, P<0.01; ***compared with the Model group, P<0.001; ****compared with the Model group, P<0.0001. DETAILED DESCRIPTION
[0025] In order to make the technical solutions and beneficial effects of the present invention more clearly understood, the following is a detailed description by listing specific embodiments. Unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application belongs.
[0026] In one aspect, the present invention provides a traditional Chinese medicine composition for treating ischemic cardiomyopathy, comprising the following raw materials in parts by weight: 1-20 parts (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.) of Pseudostellaria heterophylla or red ginseng, 10-50 parts (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.) of Astragalus membranaceus. 2, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, etc.), 5 to 30 parts of Ophiopogon japonicus (for example, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, etc.), 1-15 parts (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 parts, etc.) of Schisandra chinensis, 1-20 parts (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 parts), stir-fried white peony root, 1-20 parts (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 parts, 16, 17, 18, 19, 20 parts, etc.), 5-15 parts (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 parts, 30 parts (for example, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, etc.), 0.1-10 parts of liquorice (for example, 0.5 parts, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, etc.).
[0027] In this specification, the "weight parts" or "parts" of each component represent the dosage ratio between the components, rather than the actual mass unit. According to the actual situation, the unit weight part or each part can be any mass, such as 1 weight part or 1 part can be 1g, 500g or 1kg, or even 15g, 30g, etc.
[0028] Unless otherwise specified, the medicinal materials, reagents, etc. used in the following examples are all commercially available products.
[0029] In certain embodiments, the Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of Pseudostellariae Radix or Red Ginseng, 15-40 parts of Astragalus, 5-25 parts of Ophiopogon japonicus, 1-10 parts of Schisandrae Chinensis, 5-15 parts of stir-fried White Peony Root, 5-25 parts of Salvia miltiorrhiza, and 1-5 parts of Licorice.
[0030] In certain embodiments, the Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of Pseudostellaria heterophylla or red ginseng, 30 parts of Astragalus, 15 parts of Ophiopogon japonicus, 6 parts of Schisandra chinensis, 10 parts of stir-fried white peony root, 15 parts of Salvia miltiorrhiza, and 3 parts of Licorice.
[0031] In certain embodiments, the Chinese medicine composition is composed of Radix Pseudostellariae, Radix Astragali, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, and Radix Glycyrrhizae, and the weight proportion of each raw material is as defined in any one of the above items.
[0032] In certain embodiments, the Chinese medicine composition is composed of red ginseng, astragalus, ophiopogon, schisandra, stir-fried white peony root, salvia miltiorrhiza, and liquorice, and the weight proportion of each raw material is as defined in any of the above items.
[0033] In one aspect, the present invention provides a pharmaceutical composition, comprising any one of the above-mentioned traditional Chinese medicine compositions.
[0034] In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0035] In one aspect, the present invention provides a method for preparing a pharmaceutical composition, wherein the bulk drug according to any of the above-mentioned weight portions is added or not added with a pharmaceutically acceptable carrier to prepare a clinically acceptable preparation.
[0036] In one aspect, the present invention provides use of any of the above-mentioned traditional Chinese medicine compositions, the above-mentioned drug combinations, or the drug compositions prepared according to the above-mentioned preparation methods in the preparation of drugs for treating ischemic cardiomyopathy.
[0037] In certain embodiments, the drug is in an oral formulation.
[0038] In certain embodiments, the oral preparation is selected from one or more of decoction, powder, capsule, tablet, honey pill, water-honey pill, water pill, concentrated pill, paste pill, wax pill, granule, oral liquid or drop pill.
[0039] In certain embodiments, the oral preparation is a decoction, a powder, a capsule or a tablet.
[0040] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually performed under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0041] Example 1
[0042] A traditional Chinese medicine composition (Shenqi Yangxin Decoction) for treating ischemic cardiomyopathy comprises the following raw materials in parts by weight: 10g of Pseudostellariae Radix, 30g of Astragalus, 15g of Ophiopogon japonicus, 6g of Schisandrae Chinensis, 10g of stir-fried White Peony Root, 15g of Salvia miltiorrhiza, and 3g of Licorice.
[0043] Preparation and usage: The Chinese medicine composition of this embodiment is prepared into a decoction according to a conventional method. Specifically, the above-mentioned raw materials are weighed according to the above-mentioned weight, water is added to submerge the medicinal materials, soaked, heated to boiling, decocted, and the decoction is taken to make a decoction - Shenqi Yangxin Decoction (Pseudostellaria baicalensis).
[0044] Example 2
[0045] A traditional Chinese medicine composition (Shenqi Yangxin Decoction) for treating ischemic cardiomyopathy comprises the following raw materials in parts by weight: 10g of red ginseng, 30g of astragalus, 15g of ophiopogon, 6g of schisandra, 10g of stir-fried white peony root, 15g of salvia miltiorrhiza, and 3g of liquorice.
[0046] Preparation and Usage The Chinese medicine composition of this embodiment is prepared into a decoction according to a conventional method. Specifically, the above-mentioned raw materials are weighed according to the above-mentioned weight, water is added to immerse the medicinal materials, soaked, heated to boiling, decocted, and the decoction is taken to make a decoction - Shenqi Yangxin Decoction (Red Ginseng).
[0047] Test Example 1
[0048] The experimental animals were 90 Sprague Dawley (SD) rats, SPF grade, 7-8 weeks old, weighing 250-300 kg, male, provided by Weitonglihua Laboratory Animal Technology Company.
[0049] Effect of Shenqi Yangxin Decoction on Cardiac Function in ICM Rats
[0050] After the rat ICM model was successfully established, 64 ICM rats were randomly divided into a model group (Moldel), high, medium and low dose groups of Shenqi Yangxin Decoction (Pseudostellariae Pseudostellariae, Example 1) (SQYX-TH, SQYX-TM, SQYX-TL, respectively), high, medium and low dose groups of Shenqi Yangxin Decoction (Red Ginseng, Example 2) (SQYX-HH, SQYX-HM, SQYX-HL, respectively), a positive control drug sacubitril valsartan sodium group (ARNI), and a sham operation group (Sham) of 10 rats, and the corresponding drugs and normal saline were gavaged once a day for 12 weeks.
[0051] After intragastric administration, the number of rats in each group was: 10 in the Sham group, 6 in the Model group, 6 in the SQYX-TH group, 7 in the SQYX-TM group, 7 in the SQYX-TL group, 7 in the SQYX-HH group, 8 in the SQYX-HM group, 6 in the SQYX-HL group, and 8 in the ARNI group.
[0052] The myocardial tissues of rats in each group were taken for H&E staining to observe the pathological changes of myocardial tissues. Figure 1 As shown in the figure, the myocardial tissue of rats in the Sham group was clearly stained, with an orderly and regular trend, and blue-stained nuclei were orderly arranged in between. The myocardial cells were uniform in size, complete in structure, and regularly arranged. Compared with the Sham group, the fiber structure of myocardial tissue in the Model group was disordered, the muscle fibers became thicker, and focal plasma condensation was observed, showing wavy changes or irregular masses. The cell membrane structure of myocardial cells was destroyed, the myocardial cells were obviously swollen, and vacuolar changes were observed. The nuclei were disordered, and nuclear condensation or fragmentation was observed. Compared with the Model group, H&E staining of each drug-treated group showed that the pathological changes of myocardial tissue were alleviated, mainly manifested in that the myocardial fibers were arranged more neatly, there were fewer tissues with wavy or irregular mass changes, the gaps between myocardial cell bundles were reduced, the degree of cell damage was reduced, and the vacuolar changes were reduced; the nuclei were arranged more neatly.
[0053] The myocardial tissues of rats in each group were taken for Masson staining to observe the degree of myocardial fibrosis and calculate the collagen volume fraction (CVF). Figure 2 As shown, the blue collagen fibers in the myocardial tissue of rats in the Model group were significantly more than those in the Sham group (P<0.0001). After treatment with corresponding Chinese medicine and ARNI, the CVF of the myocardial tissue of ICM rats in each drug-treated group was significantly lower than that in the Model group (P<0.0001).
[0054] The results showed that the Chinese medicine compositions of Example 1 and Example 2 provided by the present invention can improve the cardiac function of ICM rats, alleviate myocardial pathological changes in ICM rats, and reduce the degree of fibrosis.
[0055] Effect of Shenqi Yangxin Decoction on the Morphology of Myocardial Mitochondria in ICM Rats
[0056] Compared with the Sham group, the rats in the Model group had obvious myocardial mitochondrial damage, with mitochondrial swelling, reduced cristae density, multiple autophagosomes, fibroblasts and smooth muscle cells in the infarct area, and disordered myocardial cells in the non-infarct area. After treatment with high, medium, and low doses of Shenqi Yangxin Decoction (Pseudostellaria pseudoginseng) and Shenqi Yangxin Decoction (Red Ginseng), the degree of mitochondrial swelling was reduced, the cristae density was increased, the myocardial fibers in the non-infarct area were arranged more neatly, and autophagosomes and lysosomes were visible, indicating that mitochondrial autophagy was reduced ( Figure 3 ). The results show that the Chinese medicine compositions of Example 1 and Example 2 provided by the present invention can improve the repair of damaged mitochondrial morphology in the myocardium of ICM rats, improve myocardial morphology, and alleviate mitochondrial autophagy.
[0057] Test Example 2
[0058] Rat cardiomyocytes H9c2 are subcloned cell lines derived from embryonic BD1X rat heart tissue, showing many characteristics of skeletal muscle cells. This cell line is derived from the heart and can be used as cardiac myoblasts for in vitro research on myocardial diseases. The H9c2 cells used in this article were purchased from Wuhan Pronocell Life Science Technology Co., Ltd.
[0059] Effects of Shenqi Yangxin Decoction on NT-proBNP and sST2 in H9c2 cardiomyocytes
[0060] After starvation treatment, H9C2 cardiomyocytes were given 200 μg / ml of Shenqi Yangxin Decoction (Pseudostellaria baicalensis, Example 1) and 200 μg / ml of Shenqi Yangxin Decoction (Red Ginseng, Example 2), respectively. The control group was given complete culture medium. After 24 hours of intervention, the cell supernatant after intervention was collected, and the changes of NT-proBNP and sST2 were detected by ELISA. The results showed that ( Figure 4 ), Shenqi Yangxin Decoction (Pseudostellaria baicalensis) and Shenqi Yangxin Decoction (Red Ginseng) can reduce the expression of NT-proBNP and sST2 in the cell supernatant, with statistically significant differences (P<0.05).
[0061] Effects of Shenqi Yangxin Decoction on mitochondrial autophagy-related mRNA and protein mediated by PINK1-Parkin pathway in H9c2 cardiomyocytes
[0062] The expression of related mRNA was detected by RT-PCR. Figure 5), under hypoxic conditions, the expression of autophagy-related genes PINK1, Parkin, Atg7, Atg12, p62 and mt-DNA were significantly increased (P<0.001). After treatment with Shenqi Yangxin Decoction (Pseudostellaria baicalensis), the expression of PINK1 decreased but there was no statistical difference (P>0.05), the expression of Parkin, Atg7, Atg12 and mt-DNA decreased significantly (P<0.001), and p62 increased significantly (P<0.001). After intervention with Shenqi Yangxin Decoction (Red Ginseng), the expression of PINK1, Parkin, Atg7, Atg12 and mt-DNA decreased significantly (P<0.01), and p62 increased significantly (P<0.01).
[0063] The expression of relevant mRNA was detected by Western blot, and the results showed that ( Figure 6 ), under hypoxic conditions, the expression of PINK1, Parkin, and p62 proteins in H9c2 cardiomyocytes decreased (P<0.05), and the LC3 II / I ratio increased (P<0.0001). Shenqi Yangxin Decoction (Pseudostellariae Radix) increased the expression of PINK1, but there was no statistical difference (P>0.05), and it could significantly increase the expression of PRKN and p62, and reduce LC3II / I (P<0.05). Shenqi Yangxin Decoction (Red Ginseng) can increase the expression of PINK1, Parkin, and p62 proteins, and reduce LC3II / I, and all of them have statistical differences (P<0.01). The results show that hypoxic conditions can promote autophagy in H9c2 cardiomyocytes, and the intervention of Shenqi Yangxin Decoction can reduce autophagy. The Chinese medicine compositions of Examples 1 and 2 provided by the present invention can inhibit the autophagy of H9c2 cardiomyocytes in the hypoxic model, thereby reducing the hypoxic damage of cardiomyocytes.
[0064] Clinical trials
[0065] 1. Research subjects
[0066] Patients with ischemic cardiomyopathy who received clinical treatment in the cardiovascular ward or outpatient clinic of the Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine from December 2021 to January 2024 were selected and divided into a ginseng and Astragalus group and a control group according to the random number table method. A total of 123 patients who underwent complete examination and intervention were included in the research subjects, including 63 cases in the ginseng and Astragalus group and 60 cases in the control group.
[0067] 2. Diagnostic criteria
[0068] (1) Western medicine diagnostic criteria: The diagnostic criteria for heart failure caused by ischemic cardiomyopathy were established with reference to the 9th edition of Internal Medicine and Advances in Diagnosis and Treatment of Ischemic Cardiomyopathy.
[0069] (2) TCM diagnostic criteria: The diagnostic criteria for the syndrome of Qi and Yin deficiency and blood stasis in heart-water disease were formulated with reference to the 2002 edition of the Guidelines for Clinical Research of New Chinese Medicines (Trial Implementation), the Expert Consensus on the Integrated Chinese and Western Medicine Diagnosis and Treatment of Chronic Heart Failure, and the Expert Consensus on the TCM Diagnosis and Treatment of Chronic Heart Failure. The main symptoms are: (1) palpitations; (2) fatigue; (3) shortness of breath / wheezing; secondary symptoms are: (1) sweating (spontaneous sweating / night sweats); (2) thirst / dry throat; (3) hot hands and feet; (4) dark purple lips; tongue: dark red or dark purple (or with ecchymosis, petechiae, or tortuous and purple veins under the tongue), thin tongue, with little or no coating or little fluid, or peeling coating, or cracks. Pulse: weak pulse or knotted or intermittent pulse. Patients who meet two or more of the main symptoms and two or more of the secondary symptoms can be diagnosed by referring to the tongue and pulse.
[0070] 3. Inclusion criteria:
[0071] (1) Meet the above diagnostic criteria;
[0072] (2) NYHA grade II to IV;
[0073] (3) Aged 18 or above;
[0074] (4) Voluntarily participate in this study and sign the informed consent.
[0075] 4. Exclusion criteria:
[0076] (1) Cardiogenic shock, severe ventricular arrhythmia, sick sinus syndrome, complete atrioventricular block, unrepaired valvular disease, constrictive pericarditis, cardiac tamponade, etc.;
[0077] (2) Patients with infectious diseases, severe liver and kidney diseases (alanine aminotransferase and aspartate aminotransferase are more than 3 times the upper limit of normal / glomerular filtration rate is less than 60ml / (min.1.732m^2)), blood system diseases, pulmonary embolism, lower extremity venous thrombosis, connective tissue diseases and autoimmune diseases;
[0078] (3) Those who are taking steroid hormones, nonsteroidal anti-inflammatory drugs and immunosuppressants;
[0079] (4) Patients with concurrent malignant tumors, AIDS, or mental illness;
[0080] (5) Women who are preparing for pregnancy, pregnant or breastfeeding;
[0081] (6) Those who are known to be allergic to the drug ingredients used in this study;
[0082] (7) Those who have participated in or are currently participating in other clinical trials in the past three months;
[0083] (8) The patient is unwilling to cooperate with the trial.
[0084] 5. Research Methods
[0085] 5.1 Case grouping
[0086] All 123 selected patients were divided into two groups according to the random number table method: a control group of 60 cases, which were treated with standard western medicine treatment; and a ginseng and astragalus group of 63 cases, which were treated with the Chinese medicine composition of the present invention in addition to the standard western medicine treatment of the control group.
[0087] 5.2 Treatment options
[0088] Both groups of patients were given health education after enrollment: low-salt and low-fat diet, smoking cessation and alcohol restriction, lifestyle adjustment, appropriate exercise, and good control of blood pressure, blood sugar, and blood lipids.
[0089] Control group: Standard Western medicine treatment can refer to the following medications: (1) Diuretics: such as furosemide, torsemide, etc., adjusted according to the patient's degree of heart failure, 24-hour intake and output, and electrolyte status;
[0090] (2) β-blockers: metoprolol, bisoprolol, etc., adjust the dose according to heart rate and blood pressure;
[0091] (3) ACEI / ARB, ARNI: such as perindopril, irbesartan, sacubitril-valsartan sodium tablets, etc. The dosage is adjusted according to blood pressure and renal function;
[0092] (4) Aldosterone receptor antagonists: spironolactone, etc., adjusted according to urine volume, renal function and electrolyte status.
[0093] (5) SGLT2i: empagliflozin, dapagliflozin, etc.;
[0094] (6) Anti-myocardial ischemia: nitrates, β-receptor blockers, non-dihydropyridine calcium channel blockers, L-carnitine, etc.;
[0095] (7) Anti-atherosclerosis: statins, fibrates, aspirin, clopidogrel, etc.;
[0096] (8) Provide oxygen therapy to correct dyspnea, correct electrolyte imbalance, and prevent various complications; patients with diabetes and hypertension can use hypoglycemic and antihypertensive drugs at the same time; when patients have hypertension, it is recommended that blood pressure be controlled below 140 / 90 mmHg; when patients have diabetes, it is recommended that fasting blood sugar fluctuate between 4.5-6.9 mmol / L.
[0097] Shenqi group: On the basis of standard Western medicine treatment, the Chinese medicine composition (Shenqi Yangxin Decoction) prepared in Example 1 was taken for treatment. The Chinese medicine used during the study was from the Chinese medicine pharmacy of the Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine. Usage: 180 ml, taken warm twice a day after meals in the morning and evening. The treatment cycle of both groups of patients was 4 weeks. During the treatment period of each group, other Chinese medicine decoctions and Chinese patent medicines were stopped.
[0098] 5.3 Observation indicators and judgment criteria
[0099] 5.3.1 Efficacy indicators
[0100] (1) The TCM symptom score table was prepared with reference to the 2002 edition of "Guidelines for Clinical Research of New Chinese Medicines (Trial)", "Expert Consensus on Diagnosis and Treatment of Chronic Heart Failure with Integrated Traditional Chinese and Western Medicine" and "Expert Consensus on Diagnosis and Treatment of Chronic Heart Failure with Traditional Chinese Medicine". The score changes of the TCM symptoms in the Shenqi group (additional administration of the TCM composition of the present invention) and the control group before and after treatment were recorded. First, the symptoms were divided into four levels: none, mild, moderate and severe. The corresponding main symptoms were recorded as 0 points, 2 points, 4 points and 6 points; the concomitant symptoms were recorded as 0 points, 1 point, 3 points and 4 points. The score was recorded once before and after treatment.
[0101] (2) Minnesota Heart Failure Quality of Life Score: The Minnesota Heart Failure Quality of Life Questionnaire, developed by the University of Minnesota in 1986, is used to assess the impact of heart failure on quality of life in the past month. Numbers from 0 to 5 represent severity. The higher the score, the more severe the severity and the worse the quality of life. Fill in the form once before and after treatment.
[0102] (3) 6-minute walk test (6MWT): Refer to the "Chinese Expert Consensus on the Clinical Application of the 6-minute Walk Test" and prepare the corresponding rescue items. Under the condition of excluding absolute contraindications, the clinical physician accompanies the patient to complete the test. If the patient has severe chest pain, dyspnea, etc., the test should be stopped immediately. Ask the patient to walk back and forth in a 30-meter-long straight corridor as fast as possible. The test should be completed in 6 minutes and the number of meters walked by the patient should be recorded. The two groups of patients were recorded before and after treatment.
[0103] (4) NYHA cardiac function classification: The NYHA cardiac function classification proposed by the New York Heart Association (NYHA) in 1928 was used to classify cardiac function impairment into four levels according to the degree of activity that causes heart failure. The improvement of NYHA cardiac function classification before and after treatment was recorded and compared between the two groups of patients.
[0104] (5) Laboratory indicators: The serum NT-proBNP, hs-CRP, IL-1β, IL-18, IL-10, IL-4 and soluble growth stimulation expression gene 2 (sST2) levels of the two groups of patients were measured before and after treatment. Serum NT-proBNP and hs-CRP were tested by the Laboratory Department of the Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi. sST2, IL-1β, IL-18, IL-10, and IL-4 were detected by ELISA.
[0105] (6) Cardiac ultrasound related indicators: The left ventricular ejection fraction (LVEF) was compared between the two groups of patients before and after treatment.
[0106] 5.3.2 Safety indicators
[0107] (1) Vital signs: body temperature, pulse, respiration, and blood pressure.
[0108] (2) Routine blood test (white blood cells, red blood cells, hemoglobin, platelets), liver function test (aspartate aminotransferase, alanine aminotransferase), renal function test (creatinine, urea, uric acid), electrolytes (potassium, sodium, chloride), and fasting glucose.
[0109] 5.3.3 Criteria for determining efficacy
[0110] (1) Criteria for determining the efficacy of TCM syndromes: The effective rate was calculated by subtracting the total score after treatment from the total score before treatment, divided by the total score before treatment. An effective rate ≥ 70% was considered markedly effective, 70% > effective rate ≥ 30% was considered effective, 30% > effective rate ≥ 0 was considered ineffective, and effective rate < 0 was considered aggravated.
[0111] (2) Criteria for determining the efficacy of cardiac function: The efficacy is classified into markedly effective, effective, ineffective, and aggravated according to the improvement of the patient's clinical manifestations and the degree of improvement of cardiac function.
[0112] (3) Criteria for judging the efficacy of the Minnesota Heart Failure Quality of Life Questionnaire, the 6-minute walk test, and laboratory indicators: Compare the data of relevant indicators before and after treatment using corresponding statistical methods. If P ≤ 0.05, the difference is statistically significant, which means it is effective; if P > 0.05, the difference is not statistically significant, which means it is ineffective.
[0113] 6. Research Results
[0114] 6.1 Evaluation of efficacy
[0115] (1) Changes in TCM syndrome scores and efficacy before and after treatment
[0116] There was no significant difference in the TCM syndrome scores of the two groups of patients before treatment (P>0.05), indicating that the baselines were comparable. After the two groups of patients received the corresponding treatment, the TCM syndrome scores were statistically analyzed and found that compared with before treatment, the TCM syndrome scores of the two groups of patients were significantly reduced after treatment (P<0.0001), and the effect of the Chinese medicine composition combined with Western medicine treatment of the present invention was more significant (P<0.05) (Table 1).
[0117] Table 1 Comparison of TCM syndrome scores between the Shenqi group and the control group before and after treatment M (P 25 ,P 75 )
[0118]
[0119]
[0120] After treatment, the total effective rate of TCM syndrome in the ginseng and astragalus group was 81%, which was significantly different from the effective rate of 60% in the control group (P < 0.05) (Table 2).
[0121] Table 2 Comparison of TCM syndrome efficacy in patients in the ginseng and astragalus group and the control group before and after treatment
[0122]
[0123] (2) Comparison of Minnesota Heart Failure Quality of Life Score in patients before and after treatment
[0124] Before treatment, there was no significant difference in the Minnesota Heart Failure Quality of Life scores between the control group and the Shenqi group (P>0.05), indicating that the data were comparable. After corresponding treatment, the Minnesota Heart Failure Quality of Life scores of the control group and the Shenqi group were significantly reduced (P<0.0001). After treatment, the scores of the Shenqi group were lower than those of the control group (P<0.01), indicating that the Chinese medicine composition combined with western medicine treatment of the present invention is better than western medicine alone in improving the quality of life of ICM patients (Table 3).
[0125] Table 3 Comparison of Minnesota Heart Failure Quality of Life Score between Shenqi Group and Control Group M (P 25 ,P 75 )
[0126] Group n Before treatment After treatment P Shenqi Group 63 28(25,35) 22.0(18,28) <0.0001 Control group 60 31(25,36) 26.0(20,33) <0.0001 P 0.139 0.001
[0127] (3) Comparison of cardiac function in patients before and after treatment
[0128] Analysis of the cardiac function (LVEF, NT-proBNP, sST2, 6-minute walk test, and cardiac function classification) of the patients before and after treatment showed that there was no significant difference in the LVEF levels between the control group and the ginseng and astragalus group before treatment (P>0.05), indicating that the data were comparable. After corresponding treatment, the LVEF of the patients in the control group and the ginseng and astragalus group were significantly improved (P<0.05). After treatment, the LVEF of the patients in the ginseng and astragalus group was higher than that in the control group, and the difference was statistically significant (P<0.05) (Table 4).
[0129] Table 4 Comparison of LVEF (%) between the Shenqi group and the control group before and after treatment 25 ,P 75 )
[0130] Group n Before treatment After treatment P Shenqi Group 63 51.00(40.0,59.75) 58.00(44.75,64.00) <0.0001 Control group 60 50.00(42.0,60.00) 53.00(44.00,61.00) 0.013 P 0.589 0.049
[0131] Before treatment, there was no significant difference in the NT-proBNP and sST2 levels between the control group and the ginseng and astragalus group (P>0.05), indicating that the data were comparable. After corresponding treatment, the NT-proBNP and sST2 levels of the control group and the ginseng and astragalus group were significantly reduced (P<0.0001). After treatment, the NT-proBNP levels of the ginseng and astragalus group were significantly lower than that of the control group (P<0.01), indicating that the Chinese medicine composition combined with western medicine treatment of the present invention is better than western medicine alone in reducing the NT-proBNP level of ICM patients (Table 5).
[0132] Table 5 Comparison of NT-proBNP (ng / L) before and after treatment in the Shenqi group and the control group 25 ,P 75 )
[0133] Group n Before treatment After treatment P Shenqi Group 63 3890.0(1520.0,7193.0) 1600.0(652.0,3465.0) <0.0001 Control group 60 4405.0(1683.3,7470.0) 3270.0(1042.0,5875.0) <0.0001 P 0.848 0.003
[0134] After treatment, the total effective rate of improvement of NYHA cardiac function classification in the Shenqi group was 79.4%, which was significantly different from the effective rate of 60.0% in the control group (P < 0.05) (Table 6).
[0135] Table 6 Comparison of cardiac function classification before and after treatment in the Shenqi group and the control group
[0136]
[0137] (4) Comparison of changes in serum inflammatory indicators in patients before and after treatment
[0138] In order to explore whether the Chinese medicine composition of the present invention and western medicine treatment can improve the patient's inflammation level, this subject uses ELISA method to detect the levels of hs-CRP, IL-10, IL-18, IL-6, and IL-1β in the patient's serum. It was found that both the Chinese medicine composition of the present invention and western medicine treatment can significantly reduce the level of inflammation, pro-inflammatory IL-1β and IL-18 significantly decreased after treatment (P<0.001), and anti-inflammatory IL-4 and IL-10 significantly increased after treatment (P<0.001), and the Chinese medicine composition of the present invention combined with western medicine treatment has a more significant effect in reducing hs-CRP and IL-1β (P<0.05) (Table 7, Table 8).
[0139] Table 7 Comparison of hs-CRP (mg / L) before and after treatment in the Shenqi group and the control group 25 ,P 75 )
[0140] Group n Before treatment After treatment P Shenqi Group 63 6.80(1.60,14.91) 2.58(0.50,7.70) <0.001 Control group 60 6.50(1.95,25.07) 3.02(1.39,9.13) <0.001 P 0.398 0.012
[0141] Table 8 Comparison of inflammatory factors in patients in the Shenqi group and the control group before and after treatment (Mean±SD)
[0142]
[0143]
[0144] Compared with Western medicine treatment alone, the combination of the composition of the present invention and Western medicine treatment can more effectively improve the TCM symptoms of patients with Qi and Yin deficiency type ICM, improve the quality of life of patients, improve the exercise tolerance of patients, improve the cardiac function of patients, and increase the cardiac ejection fraction. The mechanism may be related to the regulation of inflammatory response.
[0145] It should be understood that the above embodiments are exemplary and are not intended to include all possible implementations included in the claims. Various modifications and changes may be made on the basis of the above embodiments without departing from the scope of the present disclosure. Similarly, the various technical features of the above embodiments may be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only express several implementations of the present invention and do not limit the scope of protection of the patent of the present invention.
Claims
1. A traditional Chinese medicine composition for treating ischemic cardiomyopathy, comprising the following raw materials in parts by weight: 1-20 parts of Pseudostellariae Radix or Red Ginseng, 10-50 parts of Astragalus, 5-30 parts of Ophiopogon japonicus, 1-15 parts of Schisandrae Chinensis, 1-20 parts of stir-fried White Peony Root, 5-30 parts of Salvia miltiorrhiza, and 0.1-10 parts of Licorice.
2. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of Pseudostellaria heterophylla or red ginseng, 15-40 parts of Astragalus membranaceus, 5-25 parts of Radix Ophiopogonis, 1-10 parts of Schisandrae Chinensis, 5-15 parts of stir-fried white peony root, 5-25 parts of Salvia miltiorrhiza, and 1-5 parts of Licorice.
3. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of Pseudostellaria heterophylla or red ginseng, 30 parts of Astragalus membranaceus, 15 parts of Radix Ophiopogonis, 6 parts of Schisandrae Chinensis, 10 parts of stir-fried white peony root, 15 parts of Salvia miltiorrhiza, and 3 parts of Licorice.
4. The Chinese medicine composition according to any one of claims 1 to 3, characterized in that The Chinese medicine composition is composed of Radix Pseudostellariae, Radix Astragali, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Radix Paeoniae Albae, Radix Salviae Miltiorrhizae and Radix Glycyrrhizae. Alternatively, the Chinese medicine composition is composed of red ginseng, astragalus, ophiopogon, schisandra, stir-fried white peony root, salvia miltiorrhiza, and liquorice, and the weight proportions of each raw material are as defined in any one of claims 1 to 3.
5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the traditional Chinese medicine composition according to any one of claims 1 to 4.
6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition further includes a pharmaceutically acceptable carrier.
7. A method for preparing a pharmaceutical composition, characterized in that: The bulk drug according to any one of claims 1 to 4, in parts by weight, with or without a pharmaceutically acceptable carrier, is prepared into a clinically acceptable preparation.
8. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4, the pharmaceutical combination according to claim 5 or 6, or the pharmaceutical composition prepared by the preparation method according to claim 7 in the preparation of a medicament for treating ischemic cardiomyopathy.
9. The use according to claim 8, characterized in that The preparation of the medicine is an oral preparation.
10. The use according to claim 9, characterized in that The oral preparation is selected from one or more of decoctions, powders, capsules, tablets, honey pills, water-honey pills, water pills, concentrated pills, paste pills, wax pills, granules, oral liquids or dropping pills, more preferably decoctions, powders, capsules or tablets.
Citation Information
Patent Citations
Medicine for treating coronary disease
CN101337017A
Traditional Chinese medicine formula for treating cardiomyopathy
CN104127672A
Medicament for treating viral myocarditis and preparation method thereof
CN111110820A
Medicinal composition for restoring cardiac collaterals and its application
CN1334121A
